{"custom_id": "2_bevacizumab_Cutaneous toxicities_0_irae_detection_irae_detection_0.0_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: I've developed an itchy rash all over my body\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 0.0, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_1_irae_detection_irae_detection_0.0_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: I've noticed some new skin bumps that aren't itchy\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 0.0, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_2_irae_detection_irae_detection_0.0_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: The raised patches on my skin seem to be getting worse\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 0.0, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_0_irae_detection_irae_detection_0.7_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: I've developed an itchy rash all over my body\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 0.7, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_1_irae_detection_irae_detection_0.7_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: I've noticed some new skin bumps that aren't itchy\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 0.7, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_2_irae_detection_irae_detection_0.7_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: The raised patches on my skin seem to be getting worse\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 0.7, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_0_irae_detection_irae_detection_1.0_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: I've developed an itchy rash all over my body\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 1.0, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_1_irae_detection_irae_detection_1.0_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: I've noticed some new skin bumps that aren't itchy\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 1.0, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
{"custom_id": "2_bevacizumab_Cutaneous toxicities_2_irae_detection_irae_detection_1.0_gpt-3.5-turbo-0125", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-3.5-turbo-0125", "messages": [{"role": "system", "content": "You are an expert Oncologist reviewing a note from the previous visit. Your task is to review the note step by step and answer the question using only a single number."}, {"role": "user", "content": "Most recent clinic note: Sample 3 (active treatment):\nEHR Context:\nAge: 68 years\nGender: Male\nCancer diagnosis: Stage IV colorectal cancer with liver metastases\nPMH: coronary artery disease, type 2 diabetes\nPrior cancer treatments: None\nCurrent cancer treatments: FOLFIRI + bevacizumab (started 2 months ago)\nCurrent medication list: metformin, aspirin, atorvastatin, metoprolol, lisinopril\nSummary of most recent oncology visit (6 weeks ago): 68-year-old male with newly diagnosed stage IV colorectal cancer with liver metastases. He is on first-line FOLFIRI + bevacizumab and tolerating treatment well. Will continue treatment as planned.\n\nPatient's reported symptoms: The raised patches on my skin seem to be getting worse\n\nBased on the patient's current use of bevacizumab, how likely is it that these symptoms represent an immune-related adverse event (irAE)? Please return the corresponding number as: 1 (very unlikely), 2 (unlikely), 3 (likely), 4 (very likely). Answer: "}], "max_tokens": 1, "temperature": 1.0, "top_p": 1.0, "frequency_penalty": 0, "presence_penalty": 0}}
